{"id":"W2995949931","doi":"10.1016/j.ygyno.2019.12.002","title":"EMR 20006-012: A phase II randomized double-blind placebo controlled trial comparing the combination of pimasertib (MEK inhibitor) with SAR245409 (PI3K inhibitor) to pimasertib alone in patients with previously treated unresectable borderline or low grade ovarian cancer","year":2019,"lang":"en","type":"article","venue":"Gynecologic Oncology","topic":"Ovarian cancer diagnosis and treatment","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":false,"ca_institutions":"Université de Montréal","funders":"","keywords":"Medicine; Clinical endpoint; Placebo; Internal medicine; Discontinuation; Adverse effect; Sorafenib; Gastroenterology; Randomized controlled trial; Combination therapy; Surgery; Hepatocellular carcinoma; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001397117,0.0006225819,0.003620704,0.0004300718,0.0002030892,0.00004065582,0.0002519432,0.0003595087,0.0008571803],"category_scores_gemma":[0.0003699827,0.0003218076,0.000221603,0.001027686,0.0002694985,0.0001792723,0.000119642,0.0004854787,0.00001810583],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001331391,"about_ca_system_score_gemma":0.001421019,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00178442,"about_ca_topic_score_gemma":0.009149679,"domain_scores_codex":[0.995356,0.0008101547,0.001479707,0.0008737509,0.0006177304,0.0008626887],"domain_scores_gemma":[0.9957161,0.001901452,0.000964253,0.0006168707,0.0005122972,0.0002890194],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9266679,0.02125738,0.04648811,0.0001061134,0.001249697,0.000100731,0.0008660231,0.001064417,0.0001193412,0.00007076618,0.0004739685,0.00153558],"study_design_scores_gemma":[0.9189558,0.06928992,0.006833321,0.0004163689,0.001439685,0.000008476301,0.0001447587,0.0008312777,0.001157202,0.0000145962,0.0005478012,0.0003608134],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9614695,0.0002570171,0.00002880393,0.003923601,0.0005821293,0.0328842,0.00003162311,0.00007175187,0.0007513359],"genre_scores_gemma":[0.9897475,0.00008971993,0.0004012881,0.0006211041,0.0001514805,0.008035074,0.0002595625,0.00006207663,0.0006321446],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04803254,"threshold_uncertainty_score":0.9999234,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02421069103510945,"score_gpt":0.3185982818749869,"score_spread":0.2943875908398774,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}